Pre-Clinical Model Showed Delayed Tumor Growth in the Presence of MatriStem UBM™ Particulate
Columbia, MD — (March 25, 2019) – ACell, Inc. today announced publication of the article entitled “A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy” in the journal Science Translational Medicine. The research was led by Matthew Wolf, Ph.D. and Jennifer Elisseeff, Ph.D. of Johns Hopkins University and sponsored by ACell. Dr. Wolf received the Young Investigator Postdoctoral Award for this work on March 23, 2019, at the Regenerative Medicine Workshop in Charleston, SC.
The pre-clinical study examined a mouse tumor growth model with and without the addition of particulate Urinary Bladder Matrix (UBM) (MicroMatrix®). The study showed that tumor growth was delayed in the presence of UBM devices. Going further, the researchers showed that immunotherapy drugs were more effective at delaying tumor growth when UBM was introduced, with tumor growth that was slower than either immunotherapy or UBM delivery alone.
“While this research is not in an area covered by our currently cleared indications, we believe it is an exciting development,” said Patrick McBrayer, President and CEO. “The research itself demonstrates the immense possibilities of our core technology in an area where there is a large opportunity to make an impact, and our sponsorship demonstrates our commitment to advancing knowledge around MatriStem UBM™ technology.”
“We are always looking for ways to explore how our platform UBM could someday be leveraged to potentially help patients in a variety of clinical settings,” said Thomas W. Gilbert, PhD, Chief Science Officer. “After further development, this discovery could potentially lead to future product opportunities supporting our company’s mission to help provide effective patient care.”
About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of medical devices for wound management and surgical soft tissue repair. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN.
MicroMatrix is the particulate form of ACell’s proprietary MatriStem UBM technology. MicroMatrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.